3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Breast cancer is a prevalent malignancy in China.
• Previous research indicated 3,6-dihydroxyflavone (3,6-DHF) elevates miR-34a in breast carcinogenesis.
• The underlying mechanism for 3,6-DHF's effect on miR-34a remained unclear.

Purpose of the Study:

• To elucidate the mechanism by which 3,6-dihydroxyflavone (3,6-DHF) influences miR-34a expression in breast carcinogenesis.
• To investigate the role of ten-eleven translocation (TET)1 in this process.

Main Methods:

• Quantitative reverse transcription PCR (qRT-PCR) to assess miR-34a and TET1-3 expression.
• Western blot and immunofluorescence to evaluate TET1 levels in cellular and animal models.
• Analysis of 5-hydroxymethylcytosine (5hmC) levels via immunofluorescence and dot blot.
• Chromatin immunoprecipitation (ChIP) to examine TET1 promoter binding.
• Experiments involving TET1 siRNA and DNA methyltransferase (DNMT)1 plasmid transfection.
• Methylation-specific PCR to detect miR-34a promoter methylation.

Main Results:

• 3,6-DHF was found to promote TET1 expression during carcinogen-induced breast carcinogenesis in cell and rat models.
• Elevated TET1 and 5hmC levels were observed in MDA-MB-231 cells treated with 3,6-DHF.
• TET1 knockdown and DNMT1 overexpression diminished the effect of 3,6-DHF on miR-34a re-expression.
• Methylation-specific PCR confirmed that TET1 siRNA and DNMT1 overexpression inhibit 3,6-DHF-mediated demethylation of the miR-34a promoter.

Conclusions:

• 3,6-DHF enhances TET1 expression by inhibiting DNMT1 and subsequent DNA hypermethylation.
• This action leads to the up-regulation of the tumor suppressor miR-34a in breast carcinogenesis.
• The findings reveal a novel mechanism involving TET1 and DNA methylation in 3,6-DHF's anti-cancer effects.